ArticleJournal of nanobiotechnology2026
Chemically programmable hybrid membrane-camouflaged acetate gossypol prodrug reprograms the hepatic microenvironment for the treatment of liver fibrosis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLiver fibrosis represents a critical pathological process in chronic liver disease for which precision therapies remain limited.
resultsHere we report a biomimetic nanodrug (RAET NPs) that integrates a reactive oxygen species (ROS)-responsive prodrug of acetate gossypol with hybrid cell membrane camouflage and aptamer-mediated targeting. RAET NPs are constructed through modular assembly: the ROS-responsive prodrug core is encapsulated within a hybrid membrane shell formed by fusing activated hepatic stellate cell (HSC)-derived exosome membranes with M1-type macrophage membranes, followed by decoration with CD44-specific nucleic acid aptamers. This design preserves the full repertoire of membrane-associated targeting proteins while incorporating synthetic aptamers for enhanced recognition specificity. Meanwhile, RAET NPs remain in an inert state under normal physiological conditions to reduce biotoxicity and are converted into active drugs only in the fibrosis-induced reactive oxygen species (ROS)-rich microenvironment, enabling controlled drug release at the lesion site. In both organoid and animal models of liver fibrosis, RAET NPs suppress HSC activation and extracellular matrix deposition, significantly attenuating disease progression.
conclusionsThis biomimetic nanomedicine offers a novel strategy for precision treatment of liver fibrosis through the synergistic function of prodrug and biomimetic delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.